| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/611096/2012 (21.9.12) |
| Publication Date | 21/09/2012 |
| Content Type | News |
|
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), on 21 September 2012, recommended the authorisation of the first medicine specifically for the symptomatic treatment of irritable bowel syndrome (IBS) in the European Union (EU). The Agency recommended that Constella (linaclotide) be authorised for adults with moderate to severe IBS with constipation (IBS-C), a common subtype of the disease. |
|
| Source Link | http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/09/news_detail_001611.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
